Oral direct anticoagulants in the treatment of nonvalvular atrial fibrillation. Results of the daily clinical practice.

Atrial fibrillation (AF) is the most common arrhythmia. It leads to significant morbidity and mortality. The new oral anticoagulants (NOAC) represent an improvement compared with standard treatment (vitamin K antagonists (AVK)) in the prevention of thromboembolic complications in patients with non-valvular AF.N